OUR TEAM
At Bio Strategy Advisors we are a team of seasoned professionals with more than 100 years of combined experience in small startups, as well as, medium and large BioTech, TechBio, MedTech, HealthTech and SpaceTech companies.
Carolina Alarco
​Founder and Principal
Carolina is a senior biotech executive with 30 years of experience in the biopharma industry in Massachusetts. Carolina serves on the Board of MassBio, the Massachusetts Biotechnology Council; Latinos in Bio, which she co-founded and now co-chairs; and the Mass General Hospital Board of Trustees (MGPO). She is also a Board Director in 3 private biotech companies: Syte.bio, Bonds Bio and Dione Antibiotics, as well as, on the Board of Advisors of Eastern Bank, a publicly traded bank in Boston. She is an Advisory Board Member for Cell and Gene Therapy at Informa Connect and E2MC ventures. She is an Angel investor, Member of TBD Angels and The Longevity Investors Network. Previously, Carolina was a Vice-President at Genzyme Corporation where she spent 15 years in progressive leadership roles until the acquisition by Sanofi in 2011. After that, she was a President at Aegerion Pharmaceuticals and then a President at Novelion Therapeutics, until their respective exits. Both were commercial-stage, publicly-traded Biotech companies. Carolina has been recently featured in the Boston Business Journal’s Women Who Lead in the Life Sciences (October 2023), in The Boston Globe as one of Amplify LatinX 100 (September 2023), in Boston Magazine as one of the one 150 Most Influential Bostonians (April 2023); in The Boston Globe as one of the leading faces of Biotech in Boston (March 2021); and in the Boston Business Journal as one of the Power 50 (November 2021). Carolina holds a BS in Business Administration from the University of Lima and a Graduate Degree from Harvard University.
Fernanda Gamero
​Marketing Specialist and Project Coordinator
Marketing, Branding & Market Research Expert
Fernanda Gamero has been with Bio Strategy for about 4 years. She is instrumental in all aspects of Commercial and Marketing Planning and Execution. She specializes in Primary and Secondary Market Research, Logo creation and Branding elements and guidelines, Deck creation and polishing, Website design and Social Media presence development, and project coordination. She is also the Marketing Specialist for Latinos in Bio, a 501(c)(3) non-profit with over 1,200 members, dedicated to amplifying the social capital of Latino/a professionals in BioPharma and the Life Sciences. She has a keen eye for graphic design, wonderful organizational skills and a superb focus on execution.
Martin Williams, Ph.D.
​​Scientific Consultant, CGT & Devices Expert
CEO & Founder, Syte.bio and Healix Instruments
Martin Williams has more than 20 years of experience in biotech, specializing in Cell and Gene Therapy, Synthetic Biology. He has been a Strategic Consultant at Bio Strategy for almost 2 years and is instrumental when it comes to assessing the scientific value of a technology, providing guidance on the R&D approach from discovery, to pre-clinical and clinical stages. Martin is the CEO and Founder of one of Bio Strategy's companies, SYTE.bio, a biotech start-up with next-generation innovative proprietary nucleic acid-based technologies (DNA and RNA) and has also founded Healix Instruments, a medical device company. He is a key partner for start-up founders during the drug or device development process, AI and data processing and pipeline prioritization.
Pablo Medina
​Pricing/Market Access & Business Strategy
Pablo Medina brings over 17 years of global experience in Biotech, Pharma, and Diagnostics across Roche and Genentech. He has worked in roles of increasing responsibilities in the U.S. Commercial Organization, leading Access Strategy, Pricing, Contracting, and Distribution and in customer-facing roles interacting with Large U.S. payers. He has led financial valuations and market fit assessments for early pipeline products. He has also had stints in LATAM as Head of Health Policy and Patient Advocacy for Latin America, engaging directly with policymakers and relevant stakeholders in Access and Reimbursement matters. He also has deep expertise in Operations having led Supply Chain, planning, and Forecasting operations in LATAM, Europe, and the U.S. Pablo is recognized for driving innovative solutions, focusing on value-added outcomes, and driving global projects.
Veronica Gibaja
Pre-Clinical Pharmacology & IND Expert
Veronica Gibaja brings over 20 years of experience in drug discovery and early development within pharma and biotech organizations. She specializes in advancing pre-clinical programs with transformative potential, addressing unmet medical needs, and integrating patient stratification strategies. Veronica has played a pivotal role in identifying, characterizing, and advancing numerous drug candidates through early development, leading cross-functional R&D teams, and delivering comprehensive non-clinical pharmacology packages critical for IND applications and first-in-human clinical trials. Notably, she contributed to the development of Tazverik® (a first-in-class EZH2 inhibitor), FDA-approved for follicular lymphoma and epithelial sarcoma, and its expansion into additional indications. She excels in developing Target Product Profiles (TPPs), conducting gap analyses for IND readiness, and performing due diligence on innovative startup grant applications in a wide array of therapeutic modalities, including small molecules, proteins, antibody-drug conjugates (ADC), and gene and cell therapies and indications such as oncology, rare diseases, neurodegenerative disorders, metabolic diseases, and inflammatory conditions. She is also an advisor to Spectrus on the integration of cellular assays with proteomics, metabolomics, and glycomics to accelerate drug discovery and partnering efforts. Veronica mentors startups through programs such as the Mass Innovation Network, BrightEdge (American Cancer Society Venture) and Nucleate.
Max Kunze
Startup Financing & BD Expert, Financial Modeler
​Max Kunze Küllmer is a strategic biotech leader, 3x founder, and Startup Fundraising & Business Development Consultant at Bio Strategy Advisors. With 8+ years of experience in VC and biotech BD, Max specializes in securing funding, forming high-impact partnerships with Strategics, and driving growth for cutting-edge biotech startups. He has been directly involved in company creation, spinning out biotech companies and incorporating them in the U.S. As both a founder and investor, Max has deep insight into the fundraising landscape, having backed companies like SpaceX and Kangaroo Biomedical (George Church’s Stealth-mode startup). His global network spans investors, VCs, and top pharmaceutical executives, making him a key resource for biotech startups looking to scale. Fluent in English and Spanish, Max leverages his expertise to help companies secure strategic partnerships and funding in the competitive life sciences sector.
Annabella Jucius
Pre-Clinical & Clinical Development Expert
Annabella is an independent clinical research consultant with over 25 years of experience in the biotechnology and pharmaceutical industry in companies like Medtronic, Boston Scientific and Stryker, supporting pre-and post-market medical devices and Phase I-IV drug trials. She utilizes her experience of clinical trial design, execution, and process improvement to drive transformation. Annabella received her Bachelor of Science in Biotechnology from Worcester Polytechnic Institute and completed graduate studies at the Massachusetts Institute of Technology. Annabella is the principal consultant at Massachusetts Medical Consulting and a strategic consultant at Bio Strategy Advisors. She’s also a member of the Havard Business Review Advisory Council, has served as senior advisory board member for Women in the Enterprise of Science and Technology (WEST) and volunteers for various organizations supporting women and young entrepreneurs in life sciences including Executive Women in Bio (EWIB), Women in Bio of Connecticut, and Latinos in Bio.
Angel Estrada, Ph.D., MSQA
Regulatory, Quality and Engineering Expert, Medical Devices
Angel Estrada is a Senior-Executive U.S. FDA, Global Regulatory Affairs and Quality Assurance and Clinical Affairs Leader, and Teaching Faculty. Dr Estrada is a member of Graduate Regulatory Affairs (GRA) Program Faculty at the College of Professional Studies (CPS) at Northeastern University, Boston. An accomplished Senior QARA executive, Angel has worked in the US, EU & Global Regulatory Affairs for Medical Devices (Class I, II, III, manufacturing and design environments) & Pharmaceuticals/ Biotechnology (Oncology), comprising over 30 years of commercial industry experience in companies like Hologic and Zimmer Biomet. Dr. Estrada is a versatile Regulatory Affairs and Quality Assurance Expert demonstrating contributions in leading communications, strategies, and negotiations for regulatory submissions processes and their market approvals interacting with the US FDA, EU, Canada, Japan, Latin America (LATAM), Asia-Pacific (APAC) and ROW Global Regulatory Agencies, representing 120+ global markets globally, including leading Quality Assurance and Post-Market compliance. Angel has been a member of APACmed, MedTech EU and several ISO committees and ASQ committees. Dr Estrada currently serves as SVP of Regulatory and Quality for Neutron Therapeutics.
Maria A. Pecchio
Biomedical Engineering Intern (SUMMER 2025)
Maria is a Biomedical Engineering Student at Wentworth Institute of Technology (WIT). At WIT, she is also a Work Study Volunteer at Biomedical & Biological Laboratory where she assists in setting up and running experiments, including testing biomedical devices, conducting tissue or cell culture experiments, and a Global Student Ambassador, hosting global events to celebrate different cultures. She is a member and volunteer in Latinos in Bio. As a Biomedical Engineering Intern at Bio Strategy Advisors, Maria will be learning from and assisting our team of Consultants in projects related to our MedTech clients. Her tasks will include conducting research on the market size and competitive landscape related to specific technologies and medical devices; conducting outreach for potential strategic transactions; analyzing CDMO proposals and creating comparative tables on Medical Device Development Timelines and Costs; assisting in the creation of Business Plans and Decks, including Competitive Landscape, etc.
